Transcriptomic analysis of digitoxin: Synergy with doxorubicin in HER2-overexpressing MDA-MB-453 breast cancer cells

• Published in: Biochimie Vol. 234; pp. 95 - 109
• Main Authors: Einbond, Linda Saxe, Huang, Kunhui, Balick, Michael, Ma, Hongbao, Gharbaran, Rajendra, Redenti, Stephen, Wu, Hsan-au
• Format: Journal Article
• Language: English
• Published: France Elsevier B.V 01.07.2025
• Subjects: Bioelectricity; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cardiac glycosides; Cell Line, Tumor; Digitoxin - chemistry; Digitoxin - pharmacology; Doxorubicin; Doxorubicin - pharmacology; Drug Synergism; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic - drug effects; Humans; Microarrays; Molecular docking; Molecular Docking Simulation; Receptor, ErbB-2 - biosynthesis; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Sodium-Potassium-Exchanging ATPase - metabolism; Synergy; Transcriptome - drug effects; cur; MEFs; H2O; Microarrays; DMSO; CI; PLC; Bioelectricity; ECG; EtOH; Doxorubicin; IP3; Molecular docking; Cardiac glycosides; ROS; Vmem; Synergy; IPA; NIGMS

The aim of this research is to further elucidate the mechanism of action of digitoxin and explore its potential synergistic effects with doxorubicin. MDA-MB-453 breast cancer cells, characterized by HER2 overexpression and low ER levels, were exposed to digitoxin at three doses (0.1 (0.13 μM), 0.2,...